Clarivate forecasts 2026 adjusted EBITDA of $865 million to $885 million after Life Sciences sale

• Clarivate forecasts fiscal 2026 revenue of $1.97 billion to $1.99 billion, excluding Life Sciences & Healthcare following its $600 million sale.
• Adjusted EBITDA is projected at $865 million to $885 million, supported by organic growth, cost discipline and disposals of lower-margin businesses.
• Adjusted diluted earnings are expected at $0.73 to $0.77 per share, with growth driven by share repurchases.
• Free cash flow is forecast at $320 million to $340 million, reflecting sale timing and higher one-time costs.
• For fiscal 2027, free cash flow is projected at $350 million to $400 million, with net leverage around 3.5–3.6 times.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarivate plc published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.